Aims: To investigate the relationship between insulin resistance (IR) and subsequent gestational hypertension (GH) or preeclampsia (PE) in normoglycemic and in gestational diabetic pregnant women. Furthermore, we tested whether this association was independent of the prepregnancy body mass index (BMI). Methods: Each participant underwent a 75-gram oral glucose tolerance test (OGTT) according to World Health Organization recommendation criteria with determination of serum glucose and C-peptide concentrations. IR was determined as a C-peptide-to-glucose ratio at the fasting (FCGR) state and at 2 h (2CGR) after load. Results: A total of 2,954 women were included with a singleton pregnancy, delivery at term, no chronic hypertension, and data on both glucose and C-peptide. Of these women, 183 (6.2%) developed GH and 49 (1.7%) PE. Gestational diabetes mellitus (GDM) was diagnosed in 6.0% of the participants. The FCGR and 2CGR were significantly higher in all women with GH, irrespective of their BMI, compared to the normotensive group; however, the PE and the normotensive groups had similar FCGR and 2CGR values. Conclusions: The present study suggests that IR at the OGTT is associated with the later development of GH; on the other hand, it is not associated with PE. These relationships are independent of the maternal BMI.

1.
American College of Obstetricians and Gynecologist: Diagnosis and management of preeclampsia and eclampsia: ACOG practice bulletin No. 33. Obstet Gynecol 2002;99:159–167.
2.
Innes KE, Wimsatt JH: Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Acta Obstet Gynecol Scand 1999;78:263–284.
3.
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadel L, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987;317:350–357.
4.
DeFronzo RA: The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologia 1981;21:165–171.
5.
Stamler R, Stamler J, Wallace F, et al: Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA 1978;240:1607–1610.
6.
Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167–174.
7.
Sivan E, Chen X, Homko CJ, et al: A longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes 1997;46:A16.
8.
Catalano PA, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, Sims EAH: Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol Endocrinol Metab 1993;264:E60–E67.
9.
Hamasaki T, Yasuhi I, Hirai M, Masuki H, Ishimaru T: Hyperinsulinaemia increases the risk of gestational hypertension. Int J Gynecol Obstet 1996;55:141–145.
10.
Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O: Serum lipoproteins, insulin and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gynecol 1995;85:353–356.
11.
Solomon C, Carroll J, Okamura K, Graves S, Seely E: Higher cholesterol and insulin levels in pregnancy are associated with increased risk for pregnancy-induced hypertension. Am J Hypertens 1999;12:276–282.
12.
Yasuhi I, Hogan WJ, Canick J, Sosa BM, Carpenter WM: Midpregnancy serum C-peptide concentration and subsequent pregnancy-induced hypertension. Diabetes Care 2001;24:743–747.
13.
Caruso A, Ferrazzani S, de Carolis S, Lucchese A, Lanzone A, de Santis L, Paradisi G: Gestational hypertension but not pre-eclampsia is associated with insulin resistance syndrome characteristics. Hum Reprod 1999;14:219–223.
14.
Salamalekis E, Vitoratos N, Makrakis E, Mastorakos G, Eleftheriadis M, Creatsas G: No association between insulin resistance and preeclampsia. J Matern Fetal Neonatal Med 2005;18:113–115.
15.
Roberts RN, Henriksen JE, Hadden DR: Insulin sensitivity in pre-eclampsia. Br J Obstet Gynaecol 1998;105:1095–1100.
16.
Innes EK, Wimsatt HJ, McDuffie R: Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet Gynecol 2001;97:905–910.
17.
Martinez Abundis E, Gonzalez Ortiz M, Quinones Galvan A, Ferrannini E: Hyperinsulinemia in glucose-tolerance women with preeclampsia: a controlled study. J Hypertens 1996;9:610–614.
18.
Montoro MN, Kjos SL, Chandler M, Peters RK, Xiang AH, Buchanan TH: Insulin resistance and preeclampsia in gestational diabetes mellitus. Diabetes Care 2005;28:1995–2000.
19.
Sowers JR, Saleh AA, Sokol RJ: Hyperinsulinemia and insulin resistance are associated with preeclampsia in African-Americans. Am J Hypertens 1995;8:1–4.
20.
Poston L: Maternal vascular function in pregnancy. J Hum Hypertens 1996;10:391–394.
21.
Roberts JM, Pearson GD, Cutler JA, Lindheimer MD: Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 2003;22:109–127.
22.
WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus (WHO/NCD/NCS/99.2). Geneva, World Health Organization, 1999.
23.
Weijers MNR, Bekedam JD, Smulders MY: Determinants of mild gestational hyperglycemia and gestational diabetes mellitus in a large Dutch multiethnic cohort. Diabetes Care 2002;25:72–77.
24.
American Diabetes Association: Consensus development conference on insulin resistance. Diabetes Care 1998;21:310–314.
25.
Legro SR, Finegood D, Dunaif A: A fasting glucose-to-insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694–2698.
26.
Davey DA, MacGillivray I: The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892–898.
27.
Belogolovkin V, Eddleman KA, Malone FD, Sulivan L, Ball RH, Nyberg DA, Comstock CH, Havkins GD, Carter S, Dugoffy L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME: The effect of low body mass index on the development of gestational hypertension and preeclampsia. J Matern Fetal Neonatal Med 2007;20:509–513.
28.
Simmons AL, Hennessy A, Gillin GA, Jeremy WR: Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and pre-eclamptic pregnancy. Br J Obstet Gynaecol 2000;107:678–685.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.